Introduction
Over the course of my Ph.D. studies, I investigated alterations in the pattern of leukocyte activation of patients with primary Sjögren's syndrome (pSS) and systemic sclerosis (SSc) compared to healthy controls.
Additionally, an inflammatory biomarker, the soluble urokinase-type plasminogen activator receptor (suPAR) was studied in the plasma of SSc patients in relation to the internal organ involvement. SSc also relates to autoimmune connective tissue diseases, and is characterized by autoimmune disorder, including microvascular injury, and excessive collagen deposition in the skin and internal organs, all of which lead to hypoperfusion and multiple organ dysfunction.
The most frequently affected organs are the skin, lung, heart, gastrointestinal tract, and the kidney. SSc was further classified into those with limited cutaneous, or diffuse cutaneous SSc according to LeRoy criteria. An early histological feature is the infiltration of the dermis by inflammatory cells (e. g. lymphocytes, fibroblasts, 
Results
During the course of the investigation of costimulatory molecules, we observed lower expression of CD28 in pSS and SSc, but in the case of the ICOS molecule, the expression was higher on CD3+ and CD4+ cells in the pSS group compared to healthy controls. The co-inhibitory CTLA-4 expression was higher on CD4+ lymphocytes in pSS, whereas the expression of PD-1 molecules was higher in both patient groups compared to T cells from healthy individuals. On the surface of CD11b+ APCs, the expression of CD80, CD86 and PD-L1 molecules were comparable with the healthy samples, but in SSc, we measured lower expression of ICOSL.
In the case of IDO, we measured elevated intracellular IDO content in CD3+ lymphocytes and higher IDO expression on the surfaces of CD11b+ monocytes in pSS.
In the SSc samples, there was no significant difference compared to the control group.
In pSS, the basal intracellular Ca 2+ level was lower in We found a relationship between the elevation of suPAR level and the presence and severity of SSc, therefore it has the potential to be an adequate activity biomarker. In light of others results supporting the close connection between suPAR level and pulmonary and microvascular involvement, the uPAR system's role in the pathomechanism of SSc is suggested.
